ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT00720876

Public ClinicalTrials.gov record NCT00720876. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT00720876
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
City of Hope Medical Center
Other
Enrollment
30 participants

Conditions and interventions

Conditions

Interventions

  • rituximab Biological
  • vorinostat Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 22, 2008
Primary completion
Jun 7, 2017
Completion
Jun 7, 2017
Last update posted
Aug 6, 2018

2008 – 2017

United States locations

U.S. sites
3
U.S. states
1
U.S. cities
3
Facility City State ZIP Site status
Tower Cancer Research Foundation Beverly Hills California 90211
City of Hope Comprehensive Cancer Center Duarte California 91010-3000
City of Hope Medical Group Pasadena California 91105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00720876, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2018 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00720876 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →